These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 21505452)
1. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Voss MA; Gordon N; Maloney S; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Berditchevski F; Sundar S Br J Cancer; 2011 May; 104(10):1611-8. PubMed ID: 21505452 [TBL] [Abstract][Full Text] [Related]
2. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888 [TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Kwon MJ; Park S; Choi JY; Oh E; Kim YJ; Park YH; Cho EY; Kwon MJ; Nam SJ; Im YH; Shin YK; Choi YL Br J Cancer; 2012 Feb; 106(5):923-30. PubMed ID: 22294188 [TBL] [Abstract][Full Text] [Related]
5. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma. Li M; Zhao L; Shen D; Li X; Wang J; Wei L Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589 [TBL] [Abstract][Full Text] [Related]
6. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer. González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154 [TBL] [Abstract][Full Text] [Related]
7. Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer. Kang BW; Lee D; Chung HY; Han JH; Kim YB J Cancer Res Clin Oncol; 2013 Nov; 139(11):1835-43. PubMed ID: 24005419 [TBL] [Abstract][Full Text] [Related]
8. CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. Nienstedt JC; Gröbe A; Lebok P; Büscheck F; Clauditz T; Simon R; Heumann A; Sauter G; Moebius C; Münscher A; Knecht R; Blessmann M; Heiland M; Pflug C Clin Oral Investig; 2017 Jun; 21(5):1503-1508. PubMed ID: 27444451 [TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097 [TBL] [Abstract][Full Text] [Related]
10. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Mauland KK; Trovik J; Wik E; Raeder MB; Njølstad TS; Stefansson IM; Oyan AM; Kalland KH; Bjørge T; Akslen LA; Salvesen HB Br J Cancer; 2011 Mar; 104(6):921-6. PubMed ID: 21343929 [TBL] [Abstract][Full Text] [Related]
11. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841 [TBL] [Abstract][Full Text] [Related]
12. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer]. Gottwald L; Kubiak R; Pasz-Walczak G; Sek P; Piekarski J; Szwalski J; Spych M; Chałubińska-Fendler J; Suzin J; Tyliński W; Jeziorski A Ginekol Pol; 2013 Feb; 84(2):95-101. PubMed ID: 23668054 [TBL] [Abstract][Full Text] [Related]
13. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma]. Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688 [TBL] [Abstract][Full Text] [Related]
15. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536 [TBL] [Abstract][Full Text] [Related]
16. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer. Tomica D; Ramić S; Danolić D; Šušnjar L; Perić-Balja M; Puljiz M J Obstet Gynaecol; 2018 Jan; 38(1):96-102. PubMed ID: 28764605 [TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875 [TBL] [Abstract][Full Text] [Related]
18. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475 [TBL] [Abstract][Full Text] [Related]
19. The Impact of Androgen Receptor Expression on Endometrial Carcinoma Recurrence and Survival. Mahdi Z; Abdulfatah E; Pardeshi V; Hassan O; Schultz D; Morris R; Cote ML; Elshaikh MA; Bandyopadhyay S; Ali-Fehmi R Int J Gynecol Pathol; 2017 Sep; 36(5):405-411. PubMed ID: 28277313 [TBL] [Abstract][Full Text] [Related]
20. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Kamat AA; Coffey D; Merritt WM; Nugent E; Urbauer D; Lin YG; Edwards C; Broaddus R; Coleman RL; Sood AK Cancer; 2009 Jun; 115(12):2684-92. PubMed ID: 19396818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]